Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
May 8, 2026
Reporting period
Not applicable
Filed with the SEC
May 11, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001100682-26-000059
Filed / recorded
May 11, 2026, 8:48 PM UTC
Added to OQRO
Oct 2, 2026, 12:27 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Issuer CIK
1100682
Ticker
CRL
Reporting person
Martin Mackay
Relationship
Director
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
May 8, 2026
Transaction code
A
Shares / units
1,407
Price per share
$177.62
Acquired / disposed
Acquired (A)
Shares owned after
17,137
Ownership form
Direct
Amendment
No
Footnotes from the filing
The grant was made in lieu of director service fees for the term commencing May 5, 2026. The restricted stock units vest upon the earlier of 5/8/2027, or the business day prior to the Company's next annual meeting of shareholders.